William Light, MD
Internal Medicine · Germantown, TNNPI 1881646099
Payments from drug & device makers
Across 445 payments — averaging $15.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$931
- Pfizer$733
- AbbVie$571
- GSK$509
- Boehringer Ingelheim$335
- plus $2K from 31 others
What the payments were for
- Food & beverage$6,80899%
- Education$971%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 85 | $1,400 |
| AstraZeneca | 58 | $931 |
| Pfizer | 50 | $733 |
| AbbVie(2 entities) | 39 | $571 |
| GSK | 34 | $509 |
| Boehringer Ingelheim | 22 | $335 |
| Sanofi-aventis U.S. LLC | 22 | $296 |
| Lilly USA, LLC | 18 | $265 |
| Merck | 21 | $254 |
| Amgen | 10 | $182 |
| Abbott | 7 | $145 |
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $137 |
| Bayer | 9 | $136 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $128 |
| Phathom Pharmaceuticals, Inc. | 5 | $75 |
| Genentech USA, Inc. | 4 | $67 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $62 |
| Shire North American Group Inc | 4 | $58 |
| Sanofi Pasteur Inc. | 2 | $56 |
| Shield Therapeutics Inc | 3 | $55 |
| Nestle Healthcare Nutrition Inc. | 3 | $53 |
| Astellas Pharma US Inc | 2 | $44 |
| Antares Pharma, Inc. | 3 | $43 |
| Exact Sciences | 3 | $41 |
| Daiichi Sankyo Inc. | 2 | $40 |
| Nalpropion Pharmaceuticals LLC | 3 | $36 |
| Supernus Pharmaceuticals, Inc. | 2 | $34 |
| Johnson & Johnson | 2 | $32 |
| Mannkind Corporation | 2 | $32 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| Amarin Pharma, Inc. | 2 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Baxter Healthcare | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| Aimmune Therapeutics, Inc. | 1 | $14 |
| Eisai Inc. | 1 | $11 |
How this compares
$6,905 in reported general payments places this provider in the 90th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 126 | $124,506 |
| OzempicSemaglutide | 95 | $98,792 |
| JardianceEmpagliflozin | 70 | $75,169 |
| TrulicityDulaglutide | 57 | $65,151 |
| JanuviaSitagliptin Phosphate | 43 | $62,801 |
| MounjaroTirzepatide | 41 | $46,888 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $35,015 |
| XareltoRivaroxaban | 21 | $21,690 |
| FarxigaDapagliflozin Propanediol | 17 | $20,513 |
| LinzessLinaclotide | 13 | $17,485 |
| Tresiba Flextouch U-100Insulin Degludec | 26 | $16,672 |
| EntrestoSacubitril/Valsartan | 13 | $14,560 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $13,104 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 16 | $12,190 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 65 | $9,257 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $733 | $130,292139 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $265 | $112,03998 claims |
| Novo NordiskOzempic | $1,400 | $98,79295 claims |
| Boehringer IngelheimJardiance | $335 | $75,16970 claims |
| MerckJanuvia, Lagevrio (Eua) | $254 | $66,80157 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $509 | $48,11860 claims |
| AstraZenecaFarxiga, Symbicort | $931 | $24,46534 claims |
| Johnson & JohnsonXarelto | $32 | $21,69021 claims |
| AbbVieLinzess, Lumigan | $571 | $20,96927 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $296 | $12,19016 claims |
| BayerKerendia | $136 | $6,90611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Germantown
- Mark McKenzieChattanooga$11.9M
- Bernard GrunstraBristol$6.4M
- Jewel WhiteKingsport$5.7M
- Judith WhiteKingsport$5.6M
- Obadias MarquezOoltewah$2.8M
- Amanda Moore MillerKnoxville$2.3M
- Rick WhilesBristol$1.5M
- John AndersonNashville$1.5M
- David MorinKingsport$1.4M
- John KirbyJefferson City$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.